# Xanthohumol as an Adjuvant Therapy in Critically Ill COVID-19 Patients

> **NCT05463393** · EARLY_PHASE1 · SUSPENDED · sponsor: **Medical University of Lublin** · enrollment: 50 (estimated)

## Conditions studied

- COVID-19 Respiratory Infection

## Interventions

- **BIOLOGICAL:** Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/

## Key facts

- **NCT ID:** NCT05463393
- **Lead sponsor:** Medical University of Lublin
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-10-01
- **Primary completion:** 2022-01-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** We are waiting for the additional founds.
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05463393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05463393, "Xanthohumol as an Adjuvant Therapy in Critically Ill COVID-19 Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05463393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*